Briacell Financial Statements From 2010 to 2026
| BCT Stock | 10.64 0.62 6.19% |
Check Briacell Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Briacell Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Briacell financial statements analysis is a perfect complement when working with Briacell Therapeutics Valuation or Volatility modules.
Briacell |
Briacell Therapeutics Corp Company Shares Outstanding Analysis
Briacell Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Briacell Therapeutics Shares Outstanding | 1.88 M |
Most of Briacell Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Briacell Therapeutics Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Briacell Therapeutics Corp has 1.88 M of shares currently outstending. This is 98.96% lower than that of the Biotechnology sector and 98.24% lower than that of the Health Care industry. The shares outstanding for all Canada stocks is 99.67% higher than that of the company.
Briacell Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Briacell Therapeutics's current stock value. Our valuation model uses many indicators to compare Briacell Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Briacell Therapeutics competition to find correlations between indicators driving Briacell Therapeutics's intrinsic value. More Info.Briacell Therapeutics Corp is rated third in return on equity category among its peers. It is rated fourth in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Briacell Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Briacell Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Briacell Therapeutics Financial Statements
Briacell Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Briacell Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Pair Trading with Briacell Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Briacell Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Briacell Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Briacell Stock
| 0.63 | FFH | Fairfax Financial | PairCorr |
| 0.57 | ENB-PFU | Enbridge Pref L | PairCorr |
| 0.56 | FFH-PJ | Fairfax Financial | PairCorr |
| 0.54 | AX-UN | Artis Real Estate | PairCorr |
| 0.53 | FFH-PI | Fairfax Financial | PairCorr |
The ability to find closely correlated positions to Briacell Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Briacell Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Briacell Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Briacell Therapeutics Corp to buy it.
The correlation of Briacell Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Briacell Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Briacell Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Briacell Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Briacell Therapeutics Correlation against competitors. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..